12:00 AM
Nov 10, 2014
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tipelukast regulatory update

MediciNova said FDA granted Orphan Drug designation to tipelukast to treat idiopathic pulmonary fibrosis (IPF). MediciNova is finalizing a protocol for a Phase II trial...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >